NO20040431L - Ny fremgangsmate for nedregulering av amyloid - Google Patents
Ny fremgangsmate for nedregulering av amyloidInfo
- Publication number
- NO20040431L NO20040431L NO20040431A NO20040431A NO20040431L NO 20040431 L NO20040431 L NO 20040431L NO 20040431 A NO20040431 A NO 20040431A NO 20040431 A NO20040431 A NO 20040431A NO 20040431 L NO20040431 L NO 20040431L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- amyloid
- app
- autologous
- vaccination
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 230000003828 downregulation Effects 0.000 title 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 4
- 238000002255 vaccination Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 238000002649 immunization Methods 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000003941 amyloidogenesis Effects 0.000 abstract 1
- 230000003942 amyloidogenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000016784 immunoglobulin production Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Det beskrives nye fremgangsmåter for bekjempelse av sykdommer som er kjennetegnet ved amyloid avleiring. Fremgangsmåtene angår generelt immunisering mot amyloid forløperprotein (APP) eller betaamyloid (AP). Immunisering utføres fortrinnsvis ved administrering av analoger av autologe APP eller AP, nevnte analoger er i stand til å indusere antistoffremstilling mot de autologe amyloidogene polypeptidene. Spesielt foretrukket som et immunogen er autolog AP som har blitt modifisert ved å introdusere et enkelt eller noen få fremmede, immunodominante og promiskuøse T-celleepitoper. Det beskrives også nukleinsyrevaksinering mot APP eller AP og i tillegg vaksinering ved anvendelse av levende vaksiner så vel som fremgangsmåter og midler som er anvendelige for vaksineringen. Slike fremgangsmåter og midler inkluderer fremgangsmåter for fremstilling av analoger og farmasøytiske preparater så vel som nukleinsyrefragmenter, vektorer, transformerte celler, polypeptider og farmasøytiske preparater.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101231 | 2001-08-20 | ||
| PCT/DK2002/000547 WO2003015812A2 (en) | 2001-08-20 | 2002-08-20 | Beta-amyloid-analogue-t-cell epitop vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20040431L true NO20040431L (no) | 2004-04-16 |
| NO335602B1 NO335602B1 (no) | 2015-01-12 |
Family
ID=35160895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20040431A NO335602B1 (no) | 2001-08-20 | 2004-01-30 | Farmasøytisk sammensetning for nedregulering av amyloid inneholdende et immunogen omfattende en polyaminosyre som induserer produksjon av antistoff mot dyrets autologe amyloid forløperprotein (APP) eller amyloid-beta (A-beta), nukleinsyrefragment kodende for polyaminosyren, vektor og transformert celle. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1363664A2 (no) |
| JP (1) | JP2004529881A (no) |
| CN (1) | CN100562338C (no) |
| AU (1) | AU2002233166B2 (no) |
| CA (1) | CA2440197A1 (no) |
| IL (1) | IL157475A0 (no) |
| NO (1) | NO335602B1 (no) |
| NZ (1) | NZ527720A (no) |
| WO (1) | WO2002066056A2 (no) |
| ZA (1) | ZA200400895B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539232A1 (en) * | 2002-09-12 | 2005-06-15 | Pharmexa A/S | Immunization against autologous ghrelin |
| EP1670509A4 (en) * | 2003-09-03 | 2007-10-31 | Dendritherapeutics Inc | MULTIPLEX VACCINES |
| WO2005046605A2 (en) * | 2003-11-07 | 2005-05-26 | University Of Rochester | Compositions and methods of treating neurological diseases |
| WO2012125567A2 (en) * | 2011-03-11 | 2012-09-20 | Flow Pharma Inc. | Vaccine formulation of mannose coated peptide particles |
| CN103665113A (zh) * | 2012-09-14 | 2014-03-26 | 深圳市安群生物工程有限公司 | 人Aβ42抗原决定簇多肽、抗原、抗体、用途及试剂盒 |
| RU2635517C1 (ru) * | 2016-09-14 | 2017-11-13 | Закрытое акционерное общество "Институт фармацевтических технологий" (ЗАО "ИФТ") | Синтетический иммуноген для защиты и лечения от зависимости от психоактивных веществ |
| US10828351B2 (en) | 2018-04-10 | 2020-11-10 | Ac Immune Sa | Anti-abeta therapeutic vaccines |
| CN112165956A (zh) * | 2018-04-10 | 2021-01-01 | Ac免疫有限公司 | 抗Aβ治疗性疫苗 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950700081A (ko) * | 1992-02-11 | 1995-01-16 | W 로우 죤 | 이중 캐리어 면역원성 구성물 |
| AU4377793A (en) * | 1992-05-20 | 1993-12-13 | Johns Hopkins University, The | Alternative receptor therapy |
| DE69918146T2 (de) * | 1998-10-05 | 2005-07-07 | Pharmexa A/S | Verfahren zur therapeutischen impfung |
-
2002
- 2002-02-19 JP JP2002565614A patent/JP2004529881A/ja active Pending
- 2002-02-19 WO PCT/DK2002/000112 patent/WO2002066056A2/en not_active Ceased
- 2002-02-19 CA CA002440197A patent/CA2440197A1/en not_active Abandoned
- 2002-02-19 EP EP02700174A patent/EP1363664A2/en not_active Withdrawn
- 2002-02-19 NZ NZ527720A patent/NZ527720A/en unknown
- 2002-02-19 IL IL15747502A patent/IL157475A0/xx unknown
- 2002-02-19 AU AU2002233166A patent/AU2002233166B2/en not_active Ceased
- 2002-08-20 CN CNB028163265A patent/CN100562338C/zh not_active Expired - Fee Related
-
2004
- 2004-01-30 NO NO20040431A patent/NO335602B1/no not_active IP Right Cessation
- 2004-02-03 ZA ZA200400895A patent/ZA200400895B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN100562338C (zh) | 2009-11-25 |
| WO2002066056A3 (en) | 2003-01-03 |
| NO335602B1 (no) | 2015-01-12 |
| IL157475A0 (en) | 2004-03-28 |
| WO2002066056A8 (en) | 2004-04-29 |
| ZA200400895B (en) | 2005-05-03 |
| JP2004529881A (ja) | 2004-09-30 |
| CN1893970A (zh) | 2007-01-10 |
| AU2002233166B2 (en) | 2006-06-29 |
| WO2002066056A2 (en) | 2002-08-29 |
| NZ527720A (en) | 2005-03-24 |
| EP1363664A2 (en) | 2003-11-26 |
| CA2440197A1 (en) | 2002-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20023961L (no) | Ny fremgangsmate for nedregulering av amyloid | |
| PL369099A1 (pl) | Nowy sposób obniżenia poziomu amyloidu | |
| MXPA02007796A (es) | Metodo novedoso para la disminucion de cuerpos amiloides. | |
| WO2001005820A3 (en) | Method for down-regulating gdf-8 activity | |
| US9795666B2 (en) | High-yield transgenic mammalian expression system for generating virus-like particles | |
| WO2020193688A2 (en) | Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof | |
| Yang et al. | Novel T-cell epitopes of ovalbumin in BALB/c mouse: potential for peptide-immunotherapy | |
| NO20040431L (no) | Ny fremgangsmate for nedregulering av amyloid | |
| DE69716240D1 (de) | Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten | |
| NO20051779L (no) | Immunisering mot autologt ghrelin | |
| Karunakaran et al. | Immunoproteomic discovery of Mycobacterium bovis antigens, including the surface lipoprotein Mpt83 as a T cell antigen useful for vaccine development | |
| US20090208522A1 (en) | Neutralizing Epitope-Based Growth Enhancing Vaccine | |
| JP2002510493A (ja) | クラミジア感染症に対するｄｎａ免疫化 | |
| EA200500480A1 (ru) | Иммунизация против аутологичного грелина | |
| AU2018386128A1 (en) | Vaccine compositions and methods of making same | |
| MY135691A (en) | Method for down-regulation of gdf-8 activity | |
| US11344614B2 (en) | Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes | |
| Rouhollah et al. | Immunological Evaluation of HIV-1 P24-Nef Harboring IFN-γas as an Adjuvant in BALB/c Mice | |
| CN103965288B (zh) | 登革病毒特异性hla-a*2402限制性表位肽及应用 | |
| Grimaldi et al. | Stimulation of pneumovirus-specific CD8+ T-cells using a non-toxic recombinant ricin delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |